Anti-HIV PNA Development
Human Immunodeficiency Virus (HIV) is the virus that causes AIDS. It is a retrovirus. HIV contains reverse transcriptase, an enzyme that converts viral RNA into DNA. Therefore, the most commonly used anti-HIV drugs currently target two key enzymes: protease and reverse transcriptase. Regulatory regions on the viral genome are critical to viral replication and gene expression, and they can become potential targets for the design and development of drugs. In this case, PNA can be used as a potential antisense agent to target these regulatory regions on the HIV genome.
Creative Peptides has accumulated rich experience in PNA development. We provide high-quality anti-HIV PNA development services and are committed to developing a variety of PNA targets for HIV treatment.
Attractive Therapeutic Targets for PNA
The front nucleotide of HIV genomic RNA contains an untranslated region, which contains several domains necessary for virus replication.
Fig.1 Organization of HIV genome (Chaubey, B. 2009)
The long terminal repeat (LTR) is composed of a unique 3'region (U3), a repeat region (R), and a unique 5'region (U5). U3-R-U5 fragments are located at both ends of the viral genome. There are also binding sites that are necessary to stimulate transcription in activated lymphocytes.
The nucleotide structure required to initiate reverse transcription is located downstream of the U5 region of the 5'LTR. This domain is the primer binding site (PBS) which is complementary to the 3'terminal nucleotide of tRNA and is involved in the initiation of reverse transcription.
Potential anti-HIV agent
Our service is aimed at the development of antisense PNAs in different conserved regions of the viral genome to achieve significant inhibition of viral replication. Although they cannot inhibit 100% of viral replication alone, the genetic function of PNA can make it anti-HIV antigen reagents.
The antisense effect of PNA is mainly caused by irreversibly binding to the target to block its target's function. Therefore, the delivery of PNA to the target in its cells is essential. We provide different strategies for PNA delivery, including combining cell transducers, Neamine carriers, etc.
Pharmacokinetic and toxicity analysis
We will study the pharmacokinetics and toxicity of the designed and synthesized PNA compounds clearly and show the result that they are non-toxic and have good inhibitory effects. These analyses can be used as the basis for preclinical evaluation of appropriate doses.
- Our success in developing the anti-HIV activity of PNA depends on two main factors. The first factor is the selection of conserved regions on the viral genome; the second is that the target region should be critical to the HIV life cycle.
- A mixture of multiple PNAs can be used to simultaneously target different conserved regions of the viral genome to establish additional antiviral effects.
- We can adopt different biological delivery strategies to expertly biologically deliver PNA to the target in its cells at a stoichiometric concentration, exerting the powerful antisense effect of PNA.
Creative Peptides provides anti-HIV PNA drug research and development services. We can research and develop multiple drug targets, use multiple strategies to deliver PNA to cell targets, and analyze their toxicity and activity to assist your development throughout the process. If you have any questions you want to consult, please feel free to contact us.
- Chaubey, B. Prospects for antisense peptide nucleic acid (PNA) therapies for HIV. Expert Opinion on Biological Therapy. 2009, 9(8):975–989.
Notice: Products and services are used only for scientific research.